189 related articles for article (PubMed ID: 17252597)
1. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review.
Hoogsteen IJ; Marres HA; Bussink J; van der Kogel AJ; Kaanders JH
Head Neck; 2007 Jun; 29(6):591-604. PubMed ID: 17252597
[TBL] [Abstract][Full Text] [Related]
2. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
Koukourakis MI; Giatromanolaki A; Sivridis E; Pastorek J; Karapantzos I; Gatter KC; Harris AL;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):67-71. PubMed ID: 15093900
[TBL] [Abstract][Full Text] [Related]
4. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments.
Hoogsteen IJ; Marres HA; van der Kogel AJ; Kaanders JH
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):385-96. PubMed ID: 17433637
[TBL] [Abstract][Full Text] [Related]
5. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.
Bussink J; Kaanders JH; van der Kogel AJ
Radiother Oncol; 2003 Apr; 67(1):3-15. PubMed ID: 12758235
[TBL] [Abstract][Full Text] [Related]
6. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia in head and neck cancer: how much, how important?
Janssen HL; Haustermans KM; Balm AJ; Begg AC
Head Neck; 2005 Jul; 27(7):622-38. PubMed ID: 15952198
[TBL] [Abstract][Full Text] [Related]
8. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.
Wijffels KI; Marres HA; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH
Oral Oncol; 2008 Apr; 44(4):335-44. PubMed ID: 17689286
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas.
Hoogsteen IJ; Peeters WJ; Marres HA; Rijken PF; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Radiother Oncol; 2005 Aug; 76(2):213-8. PubMed ID: 16112214
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review.
Silva P; Homer JJ; Slevin NJ; Musgrove BT; Sloan P; Price P; West CM
Clin Otolaryngol; 2007 Oct; 32(5):337-45. PubMed ID: 17883552
[TBL] [Abstract][Full Text] [Related]
11. Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas.
Secades P; Rodrigo JP; Hermsen M; Alvarez C; Suarez C; Chiara MD
Genes Chromosomes Cancer; 2009 May; 48(5):441-54. PubMed ID: 19235921
[TBL] [Abstract][Full Text] [Related]
12. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.
Sasaki Y; Kjellén E; Mineta H; Wennerberg J; Ekblad L
Acta Oncol; 2009; 48(7):1062-9. PubMed ID: 19412811
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.
Raleigh JA; Chou SC; Calkins-Adams DP; Ballenger CA; Novotny DB; Varia MA
Clin Cancer Res; 2000 Mar; 6(3):855-62. PubMed ID: 10741707
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer.
Dellas K; Bache M; Pigorsch SU; Taubert H; Kappler M; Holzapfel D; Zorn E; Holzhausen HJ; Haensgen G
Strahlenther Onkol; 2008 Mar; 184(3):169-74. PubMed ID: 18330514
[TBL] [Abstract][Full Text] [Related]
15. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking?
Mayer A; Höckel M; Vaupel P
Strahlenther Onkol; 2006 Sep; 182(9):501-10. PubMed ID: 16944371
[TBL] [Abstract][Full Text] [Related]
16. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization.
Burstein DE; Nagi C; Kohtz DS; Lee L; Wang B
Histopathology; 2006 May; 48(6):717-22. PubMed ID: 16681688
[TBL] [Abstract][Full Text] [Related]
17. Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Le QT; Shi G; Cao H; Nelson DW; Wang Y; Chen EY; Zhao S; Kong C; Richardson D; O'Byrne KJ; Giaccia AJ; Koong AC
J Clin Oncol; 2005 Dec; 23(35):8932-41. PubMed ID: 16219933
[TBL] [Abstract][Full Text] [Related]
18. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma.
Winter SC; Shah KA; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
Clin Cancer Res; 2005 Nov; 11(21):7614-20. PubMed ID: 16278379
[TBL] [Abstract][Full Text] [Related]
19. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
[TBL] [Abstract][Full Text] [Related]
20. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
